Skip to main content

Interview Questions

Pharmacovigilance Interview Questions and Answers

Drug safety interviews are timeline-driven. You will be asked to classify a case as serious or non-serious, state the reporting clock for a fatal spontaneous case, and explain how a signal moves from detection to validation.

Every answer below states the rule and the regulatory consequence of missing it.

10 questions with model answers · Updated for current GMP and ICH expectations

What this round covers

  • ICSR intake and triage
  • Seriousness, causality and expectedness
  • E2B and reporting timelines
  • Signal detection and validation
  • PSUR, PBRER and DSUR

10 Pharmacovigilance interview questions with answers

  1. Q1BasicsBeginner

    Pharmacovigilance is defined by WHO as the science relating to:

    Model answer: PV covers the full lifecycle of detecting, assessing, understanding and preventing adverse effects.

    • Patient safety focus
    • Lifecycle activity
    • Regulatory obligation
  2. Q2BasicsBeginner

    An adverse event differs from an adverse drug reaction because an AE:

    Model answer: An AE is any untoward medical occurrence; an ADR implies at least a reasonable causal relationship.

    • Causality assessment
    • Temporal relationship
    • Reporting implications
  3. Q3SeriousnessBeginner

    Which of the following makes a case serious?

    Model answer: Seriousness criteria include death, life-threatening, hospitalisation, disability, congenital anomaly and medically important events.

    • Six criteria
    • Medically important list
    • Expedited timelines
  4. Q4ICSRBeginner

    A valid ICSR requires minimum criteria of:

    Model answer: All four elements must be present for a case to be valid and reportable.

    • Follow-up for missing data
    • Non-valid case handling
    • Documentation
  5. Q5SUSARIntermediate

    Serious unexpected suspected adverse reactions from clinical trials must be reported within:

    Model answer: Fatal/life-threatening SUSARs are reported within 7 days, others within 15 days.

    • Clock start at day 0
    • Follow-up reports
    • Regulatory portals
  6. Q6TimelinesIntermediate

    Day 0 for expedited reporting is:

    Model answer: The clock starts when any employee of the company first becomes aware of a valid case.

    • Awareness definition
    • Affiliate obligations
    • Documentation of receipt
  7. Q7TimelinesIntermediate

    Expedited reporting of post-marketing serious unexpected ADRs is generally within:

    Model answer: Serious unexpected post-marketing cases are reported within 15 calendar days.

    • Expectedness vs RSI
    • Regional variations
    • Follow-up reporting
  8. Q8ExpectednessAdvanced

    Expectedness of a reaction is determined against:

    Model answer: Expectedness is assessed against the applicable reference safety information.

    • RSI version control
    • Trial vs marketed product
    • Impact on reporting
  9. Q9CausalityIntermediate

    The Naranjo algorithm is used for:

    Model answer: Naranjo scores probability of causality (definite, probable, possible, doubtful).

    • Dechallenge/rechallenge
    • Alternative causes
    • Documented rationale
  10. Q10CausalityIntermediate

    WHO-UMC causality categories include:

    Model answer: WHO-UMC uses certain, probable/likely, possible, unlikely, conditional and unassessable.

    • Temporal plausibility
    • Dechallenge
    • Other explanations

Rehearse these answers out loud

The remaining 88 Pharmacovigilance questions run inside the AI Interview Simulator, which adapts difficulty to your answers and scores your response against the same key points shown above. Creating a free account takes a minute — no card required.

Other pharma interview departments